Alvotech

Is Alvotech technically bullish or bearish?

As of July 31, 2025, Alvotech's trend has shifted to bearish, indicated by negative signals from MACD, Bollinger Bands, and moving averages, while it has significantly underperformed the S&P 500 with a year-to-date return of -40.89%.

As of 31 July 2025, the technical trend for Alvotech has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: both the weekly and monthly MACD are bearish, Bollinger Bands are bearish across both time frames, and daily moving averages also signal bearishness. The KST is bearish on both weekly and monthly charts, while Dow Theory and OBV indicate a mildly bearish trend. <BR><BR>In terms of performance, Alvotech has underperformed the S&P 500 significantly, with a year-to-date return of -40.89% compared to the S&P 500's 12.22%, and a one-year return of -29.36% against the S&P 500's 17.14%.

Is Alvotech overvalued or undervalued?

As of November 16, 2022, Alvotech is considered overvalued and risky due to its high P/E ratio of 33 compared to the industry average, negative book value, and poor stock performance, with a year-to-date return of -30.99%.

As of 16 November 2022, Alvotech's valuation grade moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company appears to be overvalued, given its P/E ratio of 33, which is significantly higher than the industry average of approximately 28.82. Additionally, the EV to EBITDA ratio stands at 31.55, further suggesting that the stock may be trading at a premium compared to its earnings potential. The PEG ratio of 0.42, while indicating growth potential, does not sufficiently offset the concerns raised by other ratios.<BR><BR>In comparison to its peers, Alvotech's valuation metrics are concerning, especially when looking at Axsome Therapeutics, which has a P/E of -20.23, and Krystal Biotech, which is considered expensive with a P/E of 25.47. The negative book value for Alvotech also raises red flags regarding its financial health. Furthermore, the company's stock has underperformed against the S&P 500, with a year-to-date return of -30.99% compared to the index's 2.44%. Overall, these factors contribute to the conclusion that Alvotech is overvalued in the current market environment.

How big is Alvotech?

As of Jun 18, Alvotech has a market capitalization of 2,782.65 million and reported net sales of 562.75 million and net profit of 96.54 million over the latest four quarters. Shareholder's funds are at -412.77 million, with total assets of 1,221.40 million as of Dec 24.

As of Jun 18, Alvotech has a market capitalization of 2,782.65 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 562.75 million, while the sum of Net Profit for the same period is 96.54 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at -412.77 million and Total Assets at 1,221.40 million.

What does Alvotech do?

Alvotech is a small-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales and profit of $110 million and a market cap of $2.78 billion. Key metrics include a P/E ratio of 33.00 and a return on equity of -31.94%.

Overview:<BR>Alvotech operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 110 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 110 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,782.65 Million <BR><BR>Key Metrics:<BR>P/E: 33.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -3.54 <BR>Return on Equity: -31.94% <BR>Price to Book: -9.21 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Alvotech?